Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

InterCure Ltd. (INCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
2.1000-0.0600 (-2.78%)
At close: 03:59PM EDT
2.0000 -0.10 (-4.76%)
After hours: 06:03PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close2.1600
Open2.1881
Bid1.8800 x 1200
Ask2.2700 x 800
Day's Range2.0600 - 2.2099
52 Week Range1.7300 - 7.5900
Volume45,560
Avg. Volume60,139
Market Cap95.703M
Beta (5Y Monthly)-0.09
PE Ratio (TTM)8.75
EPS (TTM)0.2400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.23
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
58% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for INCR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Intercure Ltd.
    HSKA: Raising target price to $93.00HESKA CORP has an Investment Rating of HOLD; a target price of $93.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

    NEW YORK, TORONTO, and HERZLIYA, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) the biggest and most profitable cannabis company outside of north America, announced today that it has filed a lawsuit against Cann Pharmaceuticals Ltd. (dba “Better”), a company with which it had previously sought to merge, to recover funds loaned and invested in the course of their dealings in connection with the merger

  • GlobeNewswire

    InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)

    NEW YORK and TORONTO and HERZLIYA, Israel, Feb. 01, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") announces that, further to the merger agreement with Cann Pharmaceutical Ltd. (“Better”) dated as of February 13, 2022, pursuant to which and subject to its terms, InterCure was to acquire 100% of the issued and outstanding shares of Better (the “Agreement”), and further to the Company’s press release dated November 23,

  • GlobeNewswire

    InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske"

    Leading Global Pharmaceutical Cannabis Company, InterCure, entered into an agreement with Praetorian Global, Inc. to license, manufacture and distribute the Florida-based cannabis brand ”Binske”NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 19, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the largest and fastest growing medical cannabis company outside of North America, today announced that it has entered into a

Advertisement
Advertisement